Although financings of over $100m have become something of a rarity for Chinese biotechs, venture capital and private equity firms, as well as pharma companies, have recently made sizeable cash injections into the hot segments of antibody-drug conjugates (ADCs) and RNA therapies.
ADC developer Bliss Biopharmaceutical (Hangzhou) Co., Ltd revealed on 6 June its Japanese partner Eisai Co., Ltd. had doubled down on its Halaven (eribulin)-loaded candidates by completing a...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?